Sugi Predict

Sugi Predict / Compounds / SCHEMBL3663950

SCHEMBL3663950

SCHEMBL3663950

CC(C)(C)OC(=O)N1CCCC1c1cccc(Br)c1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.53
▸ RIPK1 Q13546 2/20 0.53
▸ UCHL1 P09936 1/20 0.50
▸ ROCK2 O75116 1/20 0.49
▸ NR1H2 P55055 3/20 0.48
▸ NR1H3 Q13133 3/20 0.48
▸ SCD5 Q86SK9 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ MAPT P10636 1/20 0.46
▸ LMNA P02545 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ KMT2A Q03164 2/20 0.44
▸ PDE5A O76074 1/20 0.44
▸ NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22505052 1.00 USP30 (0.53) USP30RIPK1UCHL1ROCK2NR1H2
SCHEMBL26926756 1.00 USP30 (0.53) USP30RIPK1UCHL1ROCK2NR1H2
SCHEMBL29641537 1.00 USP30 (0.53) USP30RIPK1UCHL1ROCK2NR1H2
SCHEMBL31578455 0.96 USP30 (0.50) USP30RIPK1UCHL1ROCK2NR1H2
SCHEMBL15447577 0.96 USP30 (0.50) USP30RIPK1UCHL1ROCK2NR1H2
SCHEMBL878861 0.86 NPSR1 (0.56) RIPK1UCHL1ROCK2NR1H2NR1H3
SCHEMBL30551328 0.85 RIPK1 (0.43) USP30RIPK1UCHL1ROCK2NR1H2
SCHEMBL17067870 0.85 RIPK1 (0.73) RIPK1UCHL1NR1H2NR1H3SCD5
SCHEMBL21207072 0.85 RIPK1 (0.53) USP30RIPK1UCHL1NR1H2NR1H3
SCHEMBL4718386 0.85 RIPK1 (0.53) USP30RIPK1UCHL1NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LTD (GB) 2026-04-02 — — US disclosed
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-10-09 — — US disclosed
EP-4587126-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION Amphista Therapeutics Ltd (GB) 2025-07-23 — — EP disclosed
EP-4536653-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME Eisai R&D Management Co., Ltd. (JP) 2025-04-16 — — EP disclosed
WO-2024057021-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LIMITED (GB) 2024-03-21 — — WO disclosed
WO-2023239906-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-12-14 — — WO disclosed
WO-2023239906-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-12-14 — — WO disclosed
EP-3183248-B1 TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-11-11 — — EP disclosed
CN-107108581-B Tieback benzamide derivatives as potent ROCK inhibitors 百时美施贵宝公司 2020-06-23 — — CN disclosed
US-10407422-B2 Triazolopyridine inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2019-09-10 — — US disclosed
US-20190023701-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL MYERS SQUIBB CO (US) 2019-01-24 — — US disclosed
US-20170226105-A1 TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2017-08-10 — — US disclosed
US-20170226105-A1 TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2017-08-10 — — US disclosed
WO-2017040449-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL-MYERS SQUIBB COMPANY (US) 2017-03-09 — — WO disclosed
WO-2016028971-A1 TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-02-25 — — WO disclosed
US-8314112-B2 Pyrrolopyrimidines and pyrrolopyridines NOVARTIS AG (CH) 2012-11-20 — — US disclosed
EP-2242756-A2 PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES Novartis AG (CH) 2010-10-27 — — EP disclosed
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines NOVARTIS AG (CH) 2009-07-16 — — US disclosed
WO-2009087225-A2 PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES NOVARTIS AG (CH) 2009-07-16 — — WO disclosed
WO-2007064749-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES SCHERING CORPORATION (US) 2007-06-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226105-A1 TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS MYLK, ROCK1, MYLK2 USP30 1477/4885RIPK1 325/4885UCHL1 895/4885
US-20190023701-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE EPX, MPO, SERPINB1 USP30 2330/4885RIPK1 4605/4885UCHL1 670/4885
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME NEU1, NEU2, NEU4 USP30 3991/4885RIPK1 3297/4885UCHL1 659/4885
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION BCL9L, RBBP9, BRD9 USP30 447/4885RIPK1 1512/4885UCHL1 261/4885
US-10407422-B2 Triazolopyridine inhibitors of myeloperoxidase EPX, MPO, SERPINB1 USP30 2330/4885RIPK1 4605/4885UCHL1 670/4885
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines ALK, ACVR1, PTPN4 USP30 4010/4885RIPK1 1408/4885UCHL1 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.